Response to Comments: MolDX: Minimal Residual Disease Testing for Cancer

This document (A58916) is a response-to-comments notice regarding the MolDX Local Coverage Determination L38822 for Minimal Residual Disease testing in cancer. It does not itself specify coverage, limitations, or documentation requirements—refer to LCD L38822 for the formal coverage policy; the comment period was 10/01/2020–11/15/2020 and the LCD became effective 12/26/2021.

"This document is a response-to-comments notice for MolDX Minimal Residual Disease (MRD) Testing for Cancer and does not itself define coverage criteria; see LCD L38822 for the active coverage deter..."

Sign up to see full coverage criteria, indications, and limitations.